Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1.

Patel D, Ahmad F, Kambach DM, Sun Q, Halim AS, Kramp T, Camphausen KA, Stommel JM.

Sci Rep. 2019 Oct 29;9(1):15458. doi: 10.1038/s41598-019-51865-8.


Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM.

Neuro Oncol. 2018 May 18;20(6):799-809. doi: 10.1093/neuonc/nox241.


LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.

Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM.

Cancer Lett. 2018 Feb 28;415:217-226. doi: 10.1016/j.canlet.2017.11.035. Epub 2017 Dec 2.


Multivariate Analysis of Radiation Responsive Proteins to Predict Radiation Exposure in Total-Body Irradiation and Partial-Body Irradiation Models.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2017 Feb;187(2):251-258. doi: 10.1667/RR14558.1. Epub 2017 Jan 24.


FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.

Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT.

Oncotarget. 2016 Nov 22;7(47):77365-77377. doi: 10.18632/oncotarget.12670.


Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis.

Smart D, Garcia-Glaessner A, Palmieri D, Wong-Goodrich SJ, Kramp T, Gril B, Shukla S, Lyle T, Hua E, Cameron HA, Camphausen K, Steeg PS.

Clin Exp Metastasis. 2015 Oct;32(7):717-27. doi: 10.1007/s10585-015-9739-9. Epub 2015 Aug 30.


Serum Amyloid A as a Biomarker for Radiation Exposure.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2015 Jul;184(1):14-23. Epub 2015 Jun 26.


Modulation of miR-21 signaling by MPS1 in human glioblastoma.

Maachani UB, Tandle A, Shankavaram U, Kramp T, Camphausen K.

Oncotarget. 2016 Aug 16;7(33):52912-52927. doi: 10.18632/oncotarget.4143.


Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A.

Mol Cancer Res. 2015 May;13(5):852-62. doi: 10.1158/1541-7786.MCR-14-0462-T. Epub 2015 Feb 26.


The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.


The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.

Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2014 Jan 1;20(1):110-9. doi: 10.1158/1078-0432.CCR-13-2136. Epub 2013 Nov 6.


Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.


Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.

Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ.

Transl Oncol. 2013 Jun 1;6(3):355-62. Print 2013 Jun.


Correlation of plasma FL expression with bone marrow irradiation dose.

Sproull M, Avondoglio D, Kramp T, Shankavaram U, Camphausen K.

PLoS One. 2013;8(3):e58558. doi: 10.1371/journal.pone.0058558. Epub 2013 Mar 7.


Combination radiotherapy in an orthotopic mouse brain tumor model.

Kramp TR, Camphausen K.

J Vis Exp. 2012 Mar 6;(61):e3397. doi: 10.3791/3397.


Radiosensitization by the novel DNA intercalating agent vosaroxin.

Gordon IK, Graves C, Kil WJ, Kramp T, Tofilon P, Camphausen K.

Radiat Oncol. 2012 Feb 27;7:26. doi: 10.1186/1748-717X-7-26.

Supplemental Content

Support Center